Talk:Lomustine

Our Cat, 13 yrs, 7,5kg, has a tumor in the backbone, preciseley bone marrow. Obviously Lomustine is also used for animals with tumors having direct impact on neurological diseases. —Preceding unsigned comment added by 92.106.156.196 (talk) 17:39, 23 February 2011 (UTC)

International perspective?

It would be useful to have an international perspective on the price of this drug in other countries. --Nbauman (talk) 18:06, 14 January 2018 (UTC)

Proposed fix for inverted causality in hepatotoxicity paragraph

Hepatotoxicity occurs due to increased levels of liver transaminases, alkaline phosphatase, and bilirubin with lumostine use. Liver enzymes and function should be monitored during use and dose should be adjusted based on toxicity levels.

This implies that abnormal clinical test parameters cause liver toxicity. I believe that the truth is the reverse: Liver toxicity causes abnormal test parameters. Indeed, when I look at the source cited at https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017588s042lbl.pdf , it reads,

Hepatic toxicity, manifested by increased levels of transaminases, alkaline phosphatase, and bilirubin occurs with Gleostine.

In other words, the clinical test parameters are manifestations (not causes) of liver toxicity.

I propose to adjust the wording of the article text to read as follows:

"Hepatotoxicity is signaled by increased levels of liver transaminases, alkaline phosphatase, and bilirubin with lomustine use. Liver enzymes and function should be monitored during use and dose should be adjusted based on toxicity levels."

This is supported by the source and better reflects the causality implied by the source.

Boatman4 (talk) 18:31, 25 September 2023 (UTC)